Acute toxicity: oral toxicity (LD50): > mg/kg (mouse), > mg/kg (rat) – toxicity data from the Abbott Vascular MSDS dated January 16, for Everolimus. SAFETY DATA SHEET. (in accordance with Regulation (EU) /). Everolimus. Version: 1. Revision date: 29/06/ Page 1 of. Material Safety Data Sheet. Section 1 – Product and Company Information. Product Name: Everolimus. Cat. Code: tlrl-eve. Company identification: InvivoGen.
|Published (Last):||16 May 2017|
|PDF File Size:||2.26 Mb|
|ePub File Size:||13.35 Mb|
|Price:||Free* [*Free Regsitration Required]|
Slightly soluble in water. It is currently used as an immunosuppressant to prevent rejection of organ transplants. Indications Everolimus is indicated for the treatment of numerous diseases and disorders. It indicated for the treatment of the following cases including both tumors and organ transplantation: It is the protein kinase at the core of this intricate and continually evolving pathway, controls cellular growth and behavior, impacting vital processes from immune reactivity to cancer progression [17, 18].
This inhibition reduces the activity of effectors downstream, which leads to a blockage in the progression of cells from G1 into S phase, and subsequently inducing cell growth arrest and apoptosis.
Everolimus also inhibits the expression of hypoxia-inducible factor, leading to a decrease in the expression of vascular endothelial growth factor [19, 20]. The result of everolimus inhibition of mTOR is a reduction in cell proliferation, angiogenesis, and glucose uptake.
Adverse reactions Some serious adverse reactions associated with Everolimus include non-infection pneumonitis, infections, severe hypersensitivity reactions, angioedema with concomitant use of ACE inhibitors, stomatitis, renal failure, impaired wound healing, metabolic disorders and myelosuppression .
Various common side effects include Bloating or swelling of the face, arms, hands, lower legs, or fee bloody nose, chest pain or tightness, chills, cough, decreased weight, diarrhea, difficult or labored breathing, difficulty with swallowing, fever, general feeling of discomfort or illness, hoarseness, lower back or side pain, painful or difficult urination, rapid everolimjs gain, sores, ulcers, or white spots on the lips, tongue, or inside the mouth and tingling of the hands or feet .
Less common side effects include bleeding eevrolimus, bloody urine, blurred vision, burning, crawling, itching, numbness, prickling, or tingling feelings, coughing up blood, extreme tiredness or weakness, fast, pounding, or irregular heartbeat or pulse, increased thirst smds urination, irregular breathing, loss of appetite, nausea, nervousness, nosebleeds, prolonged bleeding from cuts, red or black, tarry stools, red or dark brown urine, slow heartbeat, stomach ache, sweating, unusual tiredness or weakness and vomiting .
Warning and precautions People who are allergic to Everolimus should ksds disabled. Since it can increase your risk of serious infections or getting certain cancers, such as lymphoma or skin cancer. The patients should ask their doctor about the specific risk [10, 23].
Patients who have the following conditions should consult for doctor for advice before administration: Since it may harm the unborn baby as well as affect fertility the capability to have childrenwomen should take effective birth control during administration of Everolimus and for at least eight weeks after stopping drugs.
MSDS of Everolimus
Should consult the doctor for advice if you want to or has become pregnant. It may also affect the fertility of men as well.
It is generally not recommended to have breast-feed during the administration eveolimus Everolimus for women [10, 23]. Motzer, Robert J, et al. Bilbao, Itxarone, et al. Ganschow, Rainer, et al. Dunn, C, and K. Efeyan, Alejo, and D.
Everolimus inhibits cytokine-mediated lymphocyte proliferation. Uses Everolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the hydroxy group everplimus a silyl-protected hydroxyethyl triflate moiety, followed by addition of an ethylhydroxy moiety to provide greater stability and bioavailability.
Like all tacrolimus analogues, everolimus binds to receptor protein, FKBP The complex then binds to mTOR preventing it from interacting with target proteins.
Everolimus is extensively cited in the literature with over 2, citations. A macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted to the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent.
Everolimus – DrugBank
Everolimus Preparation Products And Raw materials. No account, fast registration.
Beijing Cooperate Pharmaceutical Co. Henan Tianfu Chemical Co. Soluble in dimethysulfoxide,ethanol and chloroform. Everolimus is a derivative of Rapamycin sirolimusand works similarly to Rapamycin as an mTOR mammalian target of rapamycin inhibitor .
Everolimus is indicated for the treatment of numerous diseases and disorders. Some serious adverse reactions associated with Everolimus include non-infection pneumonitis, infections, severe hypersensitivity reactions, angioedema with concomitant use of ACE inhibitors, stomatitis, renal failure, impaired wound healing, metabolic disorders and myelosuppression .
People who are allergic to Everolimus should be disabled. Macrolide immunosuppressant; derivative of Rapamycin. Inhibits cytokine-mediated lymphocyte proliferation. Everolimus Macrolide immunosuppressant; Everolimus is a derivative of Rapamycin. Everolimus is a semi-synthetic macrocyclic lactone prepared from rapamycin by selective alkylation of the hydroxy group with a silyl-protected hydroxyethyl triflate moiety, followed by addition of an ethylhydroxy moiety to provide greater stability and bioavailability.
Everolimus Related Product Information.